Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Apr
9
2020
COVID-19 Unsympathetic to TSCA Compliance Keller and Heckman LLP
Apr
9
2020
“Method of Preparation” Claims Found Patent-Eligible Under §101 McDermott Will & Emery
Apr
9
2020
United States Intervenes and Settles Qui Tam False Claims Act Case Against Compound Pharmacies for $426,000 Kohn, Kohn & Colapinto
Apr
9
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies Sheppard, Mullin, Richter & Hampton LLP
Apr
8
2020
National Academies Publish Quadrennial Review of NNI Bergeson & Campbell, P.C.
Apr
8
2020
DOT Issues COVID-19 Enforcement Discretion for Cylinder Requalification Requirements Keller and Heckman LLP
Apr
8
2020
La Croix Loses Rule 11 Battle but Wins War, as Plaintiff Retracts Lawsuit Allegations Proskauer Rose LLP
Apr
8
2020
COVID-19 Update: When Computers Invent: How the Use of Artificial Intelligence to Treat COVID-19 Highlights Novel Inventorship Issues Cadwalader, Wickersham & Taft LLP
Apr
8
2020
Making Sense of FDA’s Recent Guidances on Personal Protective Equipment (PPE) Womble Bond Dickinson (US) LLP
Apr
8
2020
USDA Decides to Initiate COOL Rulemaking to Clear Consumer Confusion Keller and Heckman LLP
Apr
8
2020
If Successful, Teva Suit Could Decrease Generic Competition ArentFox Schiff LLP
Apr
7
2020
Personalized Medicine Coalition Releases Spring 2020 Newsletter Amid COVID-19 Foley & Lardner LLP
Apr
7
2020
Nota Bene Episode 73: “Quarantine and Chill”: Will COVID-19 Impact the Cannabis Industry? with Whitney Hodges Sheppard, Mullin, Richter & Hampton LLP
Apr
7
2020
Supreme Court Will Address Personal Jurisdiction After States Courts Interpret BMS Decision ArentFox Schiff LLP
Apr
7
2020
FDA Temporarily Relaxes Policies Relating to Eggs Produced for and Sold in the Retail Market Keller and Heckman LLP
Apr
6
2020
CARES Act Prompts Changes to Employer-Sponsored Health Plans Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Apr
6
2020
U.S. Department of Justice Issues First COVID-19-Related Business Review Letter to Medical Supplies Distributors Mintz
Apr
6
2020
CMS “Hospitals Without Walls” Waiver: Looking To ASCs to Provide Relief Sheppard, Mullin, Richter & Hampton LLP
Apr
6
2020
Push Back on Plastic Bag Bans Keller and Heckman LLP
Apr
6
2020
Novel Virus Brings Novel Coverage Theories ArentFox Schiff LLP
Apr
6
2020
COVID-19 Liability Immunity - What You Need to Know Now Womble Bond Dickinson (US) LLP
Apr
6
2020
EPA Takes Action to Ease the Production of Disinfectants Approved for Use Against the Novel Coronavirus Beveridge & Diamond PC
Apr
6
2020
FDA Policy Provides Enforcement Relief Regarding Certain Medical Devices Due to Pandemic Beveridge & Diamond PC
Apr
6
2020
EPA Highlights Enforcement Against Disinfectant Products Making Fraudulent Coronavirus Claims Beveridge & Diamond PC
Apr
6
2020
FDA Resumes Records Review Under the FSVP Rule by Remote Inspections Instead of Onsite Visits to Importers Keller and Heckman LLP
Apr
3
2020
COVID-19: Notable Impacts for Post-Acute Providers from the CARES Act, CMS Blanket Waivers, and the CMS Interim Final Rule
Apr
3
2020
Commercial Payors and Medicaid Telehealth Billing Womble Bond Dickinson (US) LLP
Apr
3
2020
FDA Funding Opportunity Announcement: “Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional” Faegre Drinker
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins